LipoSeuticals, Inc. (LSI), a Monmouth Junction, N.J.-based specialty pharmaceutical company, closed a financing round for an undisclosed amount.
The round was led by Delos Capital, a Hong Kong based life sciences fund. In conjunction with the funding, Dr. Lan Bo Chen, will be joining LSI’s Board representing Delos Capital.
Founded in 2012, LipoSeuticals is engaged in the development, manufacturing and commercialization of parenteral drug products based on its proprietary patented sugar-lipid polymer-based formulation platform, Sulocence® – a drug delivery technology that enhances drug stability and solubility. The company is currently applying the sugar-lipid technology to the reformulation of a number of marketed specialty
Led by Dr. Nian Wu, founder and inventor of the Sulocence® technology platform and Chief Executive Officer, the company intnds to use the funds to continue to develop its pipeline.